Prevention & lipids

Validation of the European SCORE2 models in a Canadian primary care cohort

Eur J Prev CardiolPublished Prediction model validation study

Authors' conclusion

The performance of SCORE2 to predict ASCVD risk in Canada varied by age group and depended on whether regional calibration was applied.

Study context

Population
Primary care cohort with routinely collected EMR data, Ontario, Canada, 2010–2014
Participants
57,409 vs 9,885
Comparison
SCORE2-YP and SCORE2-OP, uncalibrated vs low-risk region recalibrated
  • SCORE2-YPn = 57,409
  • SCORE2-OPn = 9,885
Outcome
Validity (discrimination and calibration) of SCORE2 for predicting atherosclerotic cardiovascular disease (ASCVD)
Follow-up
5 years
Methodological detailsretrospective cohort, external validation, primary care EMR data
  • Retrospective cohort
  • External validation
  • Primary care EMR data

Performance

As reported in the abstract

Five-year ASCVD prediction performance
Test or modelC-statistic, womenC-statistic, menUncalibrated: overestimated risk, womenUncalibrated: underestimated risk, menLow-risk recalibrated: overestimated risk, womenLow-risk recalibrated: overestimated risk, menUncalibrated: overestimated risk, both sexes
SCORE2-YP0.740.6917%2%100%36%
SCORE2-OP0.640.6260%13%>100%

C-statistic, women

SCORE2-YP0.74
SCORE2-OP0.64

C-statistic, men

SCORE2-YP0.69
SCORE2-OP0.62

Uncalibrated: overestimated risk, women

SCORE2-YP17%
SCORE2-OP— not stated in the abstract

Uncalibrated: underestimated risk, men

SCORE2-YP2%
SCORE2-OP— not stated in the abstract

Low-risk recalibrated: overestimated risk, women

SCORE2-YP100%
SCORE2-OP60%

Low-risk recalibrated: overestimated risk, men

SCORE2-YP36%
SCORE2-OP13%

Uncalibrated: overestimated risk, both sexes

SCORE2-YP— not stated in the abstract
SCORE2-OP>100%

Original publication

Validation of the European SCORE2 models in a Canadian primary care cohort. Eur J Prev Cardiol. Published 8 November 2023. doi:10.1093/eurjpc/zwad352

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.